Every Form 4 that Harmony Biosciences Holdings, Inc. (HRMY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HRMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRMY filings page.
Harmony Biosciences Holdings, Inc. (HRMY) reported that Chief Medical Officer Kumar Budur exercised stock options for a total of 22,954 shares of common stock on September 8, 2026, at exercise prices of $30.69 and $30.27 per share. On September 4 and 8, 2026, he sold an aggregate of 33,954 shares of common stock in open-market transactions at weighted average prices between approximately $41.51 and $43.20 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan.
Harmony Biosciences Holdings, Inc. director Germano Geno J received a grant of stock options as equity compensation. The award covers 21,231 options for common stock at an exercise price of $30.76 per share and expires on May 14, 2036. These options vest in 36 equal monthly installments beginning on June 14, 2026. Following this grant, he holds 21,231 stock options directly, with no open-market share purchases or sales reported in this filing.
Harmony Biosciences Holdings, Inc. reported that director Linda M. Szyper received a grant of stock options covering 21,872 shares of common stock at an exercise price of $30.76 per share. These options expire on May 14, 2036 and represent compensation rather than an open‑market purchase.
The option vests in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant, as long as Szyper continues in service through that date. Following this award, she holds 21,872 derivative securities directly tied to Harmony Biosciences common stock.
Harmony Biosciences Holdings, Inc. director Philip Ron M reported a compensation-related grant of stock options. He was awarded 21,872 stock options for Common Stock with an exercise price of $30.76 per share, all held directly after the grant.
The options expire on May 14, 2036 and will vest in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant, subject to his continued service. This filing reflects an acquisition of derivative securities, not an open-market share purchase or sale.
Harmony Biosciences Holdings director Graf R. Mark received a new stock option grant covering 21,872 shares of common stock. The options have an exercise price of $30.76 per share and expire on May 14, 2036. They vest in full on the earlier of May 14, 2027 or the next annual meeting, subject to his continued service. After this grant, he holds 21,872 stock options directly according to this filing.
Harmony Biosciences Holdings, Inc. director Juan A. Sabater received a grant of stock options as part of his compensation. He was awarded options for 21,872 shares of common stock at an exercise price of $30.76 per share, giving him the right to buy shares at that price in the future. These options vest in full on the earlier of May 14, 2027 or the date of the next annual meeting after the grant, as long as he continues to serve through that vesting date. After this grant, he holds 21,872 stock options directly.
Harmony Biosciences Holdings, Inc. director Gary Sender reported a grant of stock options covering 21,872 shares of common stock. The options have an exercise price of $30.76 per share and expire on May 14, 2036. They vest in full on the earlier of May 14, 2027 or the next annual meeting following the grant date, subject to continued service. This is a compensation-related award rather than an open-market trade.
Harmony Biosciences Holdings, Inc. chief medical officer Kumar Budur exercised 18,750 restricted stock units into common stock and had 8,882 shares withheld by the company to cover income tax obligations tied to the vesting. These are compensation-related, non‑market transactions rather than open‑market buying or selling.
Following the transactions, Budur directly owns 24,115 shares of common stock. The filing also corrects previously misstated common stock and derivative holdings, and confirms that the RSU award granted on May 1, 2024 vests in four equal annual installments beginning May 1, 2025.
Harmony Biosciences Holdings, Inc. reported that Chief Financial Officer Glenn Reicin received a grant of stock options covering 164,309 shares of common stock. The options have an exercise price of $29.29 per share and expire on April 14, 2036.
According to the vesting terms, 25% of the underlying shares vest on April 14, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to his continued service. Following this award, Reicin holds 164,309 stock options directly.
Harmony Biosciences Holdings, Inc. reported that Chief Commercial Officer Adam H. Zaeske exercised restricted stock units into common stock and had shares withheld for taxes. On April 7, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a stated price of $0.00 per share, reflecting a stock-based compensation event rather than a market purchase.
To cover required income tax withholdings tied to the RSU vesting, 3,173 shares of common stock were disposed of at $27.62 per share through issuer withholding, leaving Zaeske with 4,327 shares of common stock held directly after these transactions. The RSU award is scheduled to vest in four equal annual installments beginning on April 7, 2026, contingent on continued service.
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.
According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.
Harmony Biosciences Holdings, Inc. director Troy A. Ignelzi reported receiving a stock option grant for 17,710 shares of common stock. The option has an exercise price of $27.74 per share and expires on April 2, 2036. This is a compensation-related award, not an open-market trade.
The option will vest in 36 equal monthly installments beginning on May 2, 2026, meaning the right to exercise the option will phase in gradually over three years.
Harmony Biosciences Holdings, Inc. disclosed that Chief Financial Officer Sandip Kapadia sold 3,746 shares of common stock on January 26, 2026 in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $37.152 under a pre-arranged Rule 10b5-1 trading plan.
After this transaction, Kapadia directly beneficially owned 24,521 shares of Harmony Biosciences common stock. The filing also notes that a previous Form 4 filed on January 26, 2026 had inadvertently misstated the post-transaction share balance, which has been corrected in this report.
Harmony Biosciences Holdings, Inc. chief financial officer Sandip Kapadia reported several equity compensation transactions. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of $36.76, and 12,200 restricted stock units (RSUs), both vesting over multiple years subject to continued service.
On January 24, 2026, 3,813 RSUs previously granted on January 24, 2024 vested and converted into the same number of common shares. Of these, 2,239 shares were withheld at $36.82 per share to cover taxes, leaving 1,574 shares of common stock directly held. On January 25, 2026, 4,725 RSUs from a January 25, 2025 grant vested, with 2,553 shares withheld for taxes at $36.82 per share and 2,172 shares retained as common stock.
Harmony Biosciences Chief Strategy Officer Andrew Serafin reported multiple equity compensation transactions and related tax withholdings. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of $36.76 per share and 12,200 restricted stock units (RSUs), both vesting over several years subject to continued service. On January 24 and 25, 2026, previously granted RSUs vested, converting into 2,500 and 2,600 shares of common stock, respectively. At each vesting date, the issuer withheld 1,116 and 1,126 shares at a price of $36.82 per share to cover income tax obligations, leaving Serafin with directly held common shares and remaining unvested RSUs that continue to vest in annual installments.
Harmony Biosciences (HRMY) chief medical officer Budur Kumar reported new equity awards and routine tax withholding transactions. On January 22, 2026, Kumar received a stock option for 42,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 with the remainder vesting quarterly until the fourth anniversary, subject to continued service. On the same date, Kumar was granted 12,200 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24 and 25, 2026, portions of earlier RSU grants vested, converting 2,188 and 2,662 RSUs into common shares. The company withheld 1,153 and 1,372 shares, respectively, at a price of $36.82 per share to satisfy income tax obligations, leaving 1,035 and 1,290 shares directly held after each event.
Harmony Biosciences Holdings, Inc. reported an insider equity grant to its Chief Commercial Officer, Adam H. Zaeske. On January 22, 2026, he received a stock option covering 56,900 shares of common stock at an exercise price of $36.76 per share, expiring on January 22, 2036.
The option vests 25% on January 22, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to continued service. On the same date, Zaeske was also granted 16,200 restricted stock units, which vest in four equal annual installments beginning January 22, 2027, each representing one share of common stock.
Harmony Biosciences Holdings, Inc. reported equity compensation and related share activity for President and CEO Jeffrey M. Dayno. On January 22, 2026, he received a stock option for 184,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 and the rest quarterly until the fourth anniversary of the grant. He was also granted 52,900 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24, 2026, 10,500 shares of common stock were issued upon vesting of previously granted RSUs, and 4,785 shares were withheld at $36.82 per share to satisfy tax obligations, leaving 5,715 shares held directly. On January 25, 2026, an additional 13,000 shares were issued from RSU vesting, with 5,654 shares withheld at $36.82 for taxes, leaving 7,346 shares held directly.
Harmony Biosciences Holdings, Inc. reported an insider sale by its chief financial officer, Sandip Kapadia. On January 15, 2026, Kapadia sold 20,961 shares of Harmony Biosciences common stock in an open-market transaction coded as a sale. The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to trade according to a preset schedule. The weighted average sale price was $35.9159 per share, with individual trades executed between $35.68 and $36.10. After this transaction, the Form 4 reports that Kapadia directly beneficially owned 0 shares of the company’s common stock.
Harmony Biosciences Holdings, Inc. reported an insider transaction by its president, CEO and director on a Form 4. On 12/12/2025, the executive exercised a stock option for 20,000 shares of common stock at an exercise price of $8.22 per share, converting the option into shares.
That same day, the executive sold 20,000 shares and an additional 5,933 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. The reported weighted average sale price was $40.1073 per share, with individual trades occurring between $40.00 and $40.28. Following these transactions, the Form 4 reports 0 shares of common stock and 0 derivative securities beneficially owned directly from this option grant.
Harmony Biosciences Holdings, Inc. (HRMY) reported an insider stock sale by its chief financial officer. On 11/21/2025, the CFO sold 3,427 shares of common stock at a price of $35 per share, coded as an open market or similar sale (transaction code "S").
After this transaction, the reporting person disclosed beneficial ownership of 0 shares, held directly. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions dated 09/30/2025. He acquired 45,000 shares upon vesting of restricted stock units (RSUs) granted on 10/04/2023, and a portion of those shares were withheld to satisfy income tax withholdings as noted. Separately, he disposed of 24,039 shares at a price of $27.56 per share, leaving him with 20,961 shares beneficially owned after the sale. The RSUs vest on a schedule: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026. The filing was signed by an attorney-in-fact on 10/02/2025.